PROQR THERAPEUTICS EO-04 Cash Flow-to-Debt Ratio
PROQR THERAPEUTICS EO-04 cash flow-to-debt ratio. PROQR THERAPEUTICS EO-04 (0PQ) has a Cash Flow-to-Debt Ratio of -0.21x as of December 2025, meaning its operating cash flow of €-13.36 Million could theoretically repay 0% of its total liabilities (€63.38 Million) in one year. See 0PQ financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PROQR THERAPEUTICS EO-04 (2021–2025)
Cash flow-to-debt ratio of PROQR THERAPEUTICS EO-04 from 2021 to 2025. Historical debt coverage capacity for PROQR THERAPEUTICS EO-04 across 5 annual periods. Check PROQR THERAPEUTICS EO-04 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
PROQR THERAPEUTICS EO-04 Cash Flow-to-Debt Ratio by Year (2021–2025)
PROQR THERAPEUTICS EO-04 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for PROQR THERAPEUTICS EO-04. For the full cash flow conversion analysis, see cash flow conversion of PROQR THERAPEUTICS EO-04.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.83x | €-52.79 Million | €63.38 Million | ▼ -81.7% |
| 2024 | -0.46x | €-36.39 Million | €79.40 Million | ▼ -305.3% |
| 2023 | 0.22x | €21.55 Million | €96.49 Million | ▲ +134.1% |
| 2022 | -0.65x | €-68.51 Million | €104.64 Million | ▼ -142.5% |
| 2021 | -0.27x | €-26.01 Million | €96.35 Million | — |